Redcuffs, one thing we all have to keep in mind is that Koos has to do everything outside of scientific research himself. Except for recent designation of Ichim as CSO, Koos is alone. Used to have Chris Mitzer, but he was fired (for unknown reasons) months ago.
Any company short of staff and having to face a significant obstacle course of getting new drugs approved for clinical trials, is going to face setbacks and time. People on iHub especially talk as if he's in total control and should do this or that and is just lazy or whatever. Koos is not playing the stock, he's trying to develop a company in a highly competitive market by himself and so time is expected to pass between filings, and learning to make corrections etc.
If you look up the PRs, SEC filings, FDA filings etc. since Feb 2013, one can see the path, complete with stumblings, that has been walked. I'm still in and not on pins and needles for an answer today because I see that things are moving forward and there are signs that the obstacles are becoming fewer instead of multiplying. Patience is needed. The stock price will be played with until the determinent piece(s) [Green light from FDA for human clinical trials] has been given either for HemaXellerate or dCellVax.
Why haven't we heard anything about dCellVax I can only guess, but here are a couple of probable reasons:
1. Koos wants to wait for Regen IPO (trading publicly) before announcing the filing of dCellVax in order to give price support.
2. After IND for HemaXellerate encountered difficulties and delays, Koos wants to get feedback from FDA and organize a response before giving news.
3. The stem cell technology being used with dCellVax is gaining more widespread news and competitors are racing for similar types of treatments. Koos may want to lay low on news until he gets confirmation of patent, or tests lined up or once again investors lined up for Regen to go public.
We think he should release news ASAP because we want the stock price to go up now, but he should be focused on what's best for the long term success of BMSN/REGEN and getting trial approval.
If it was a company of 50 full time employees, I would expect news would be more regular and more items to have news on, but everyone invested in BMSN/REGEN should know and realize that this is basically a one man show who has contracted with scientists to try to bring promising research to product.
Any company short of staff and having to face a significant obstacle course of getting new drugs approved for clinical trials, is going to face setbacks and time. People on iHub especially talk as if he's in total control and should do this or that and is just lazy or whatever. Koos is not playing the stock, he's trying to develop a company in a highly competitive market by himself and so time is expected to pass between filings, and learning to make corrections etc.
If you look up the PRs, SEC filings, FDA filings etc. since Feb 2013, one can see the path, complete with stumblings, that has been walked. I'm still in and not on pins and needles for an answer today because I see that things are moving forward and there are signs that the obstacles are becoming fewer instead of multiplying. Patience is needed. The stock price will be played with until the determinent piece(s) [Green light from FDA for human clinical trials] has been given either for HemaXellerate or dCellVax.
Why haven't we heard anything about dCellVax I can only guess, but here are a couple of probable reasons:
1. Koos wants to wait for Regen IPO (trading publicly) before announcing the filing of dCellVax in order to give price support.
2. After IND for HemaXellerate encountered difficulties and delays, Koos wants to get feedback from FDA and organize a response before giving news.
3. The stem cell technology being used with dCellVax is gaining more widespread news and competitors are racing for similar types of treatments. Koos may want to lay low on news until he gets confirmation of patent, or tests lined up or once again investors lined up for Regen to go public.
We think he should release news ASAP because we want the stock price to go up now, but he should be focused on what's best for the long term success of BMSN/REGEN and getting trial approval.
If it was a company of 50 full time employees, I would expect news would be more regular and more items to have news on, but everyone invested in BMSN/REGEN should know and realize that this is basically a one man show who has contracted with scientists to try to bring promising research to product.
